Slingshot members are tracking this event:
Priority Review Status Granted by Health Canada for irinotecan liposome injection (nal-IRI) for New Drug Submission; review expected to be complete in the second half of 2016
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
Slingshot Insights Explained
Mar 11, 2017
Don’t see a project related to the catalyst you care about?
Related Keywords Priority Review, Health Canada, Metastatic Pancreatic Cancer, Mpac, Nds, Irinotecan Liposome Injection, Nal-iri